Table 2.
Summary of subject baseline characteristics.
| All | Treatment | SMD | ||||
|---|---|---|---|---|---|---|
| PL | NB | |||||
| DPP-4i | GLP-1RA | DPP-4i | GLP-1RA | |||
| N | 1317 | 317 | 316 | 345 | 339 | – |
| Sex, n (%) | ||||||
| Female | 726 (55.1%) | 159 (50.2%) | 179 (56.6%) | 195 (56.5%) | 193 (56.9%) | 0.068 |
| Male | 591 (44.9%) | 158 (49.8%) | 137 (43.4%) | 150 (43.5%) | 146 (43.1%) | |
| Grouped race, n (%) | ||||||
| White/Caucasian | 1119 (85.0%) | 262 (82.6%) | 278 (88.0%) | 286 (82.9%) | 293 (86.4%) | 0.135 |
| Black/African American | 165 (12.5) | 44 (13.9%) | 31 (9.8%) | 54 (15.7%) | 36 (10.6%) | |
| Other or unknown | 33 (2.5%) | 11 (3.5%) | 7 (2.2%) | 5 (1.4%) | 10 (2.9%) | |
| Age, years (SD) | 60.7 (7.0) | 61.3 (7.1) | 60.4 (6.6) | 60.9 (7.5) | 60.1 (6.7) | 0.101 |
| BMI, kg/m2 (SD) | 37.5 (5.4) | 37.3 (5.1) | 38.0 (5.6) | 36.9 (5.2) | 37.9 (5.5) | 0.121 |
| Weight, kg (SD) | 107.0 (19.4) | 106.2 (18.5) | 109.0 (20.4) | 105.1 (19.2) | 107.7 (19.4) | 0.116 |
| Waist circumference, cm (SD) | 120.2 (13.1) | 119.5 (12.3) | 121.4 (13.5) | 119.2 (13.2) | 121.0 (13.3) | 0.102 |
| Systolic blood pressure, mmHg (SD) | 124.9 (12.7) | 125.2 (12.7) | 125.2 (13.2) | 126.4 (12.3) | 122.8 (12.6) | 0.141 |
| Diastolic blood pressure, mmHg (SD) | 73.7 (8.9) | 73.4 (8.5) | 74.4 (8.5) | 73.6 (9.0) | 73.6 (9.3) | 0.058 |
| Heart rate, bpm (SD) | 74.7 (10.7) | 73.6 (11.0) | 76.4 (10.2) | 72.8 (10.4) | 75.9 (10.8) | 0.21 |
| Hemoglobin A1c, % (SD) | 7.5 (1.5) | 7.7 (1.5) | 7.5 (1.5) | 7.5 (1.5) | 7.4 (1.3) | 0.09 |
| Glucose at baseline, mmol/L (SD) | 8.8 (3.8) | 9.1 (3.8) | 8.5 (3.7) | 9.1 (3.7) | 8.6 (3.8) | 0.107 |
All values are means unless otherwise stated.
BMI body mass index, DPP4i dipeptidyl peptidase IV inhibitor, GLP1 RA glucagon-like peptide-1 receptor agonist, NB extended-release naltrexone/extended-release bupropion 32/360 mg, PL placebo, SD standard deviation, SMD standardized mean difference.